Jan 04, 2021 3:08pm EST US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Jan 04, 2021 12:05pm EST OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
Dec 31, 2020 8:30am EST Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program
Oct 29, 2020 4:05pm EDT OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results
Oct 20, 2020 8:00am EDT OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test
Oct 13, 2020 12:51pm EDT OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020
Oct 09, 2020 8:00am EDT OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools
Oct 08, 2020 11:38am EDT Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency